Comparing the current results to its competitors, Oncternal Therapeutics Inc reported Revenue increase in the 3 quarter 2024 by 175.98 % year on year. The sales growth was above Oncternal Therapeutics Inc 's competitors' average revenue growth of 11.29 %, achieved in the same quarter.
Oncternal Therapeutics Inc , slower than the average decrease reported by the company's competitors of -3.21 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -3.21 %
Due to outstanding performance in Overall company, revenue grew by 175.98 % Oncternal Therapeutics Inc improved its market share, to approximately 0 %.
May 30, 2024
Oncternal Advances Phase 1/2 Study of ONCT-534 for Treatment of Metastatic Castration-Resistant Prostate CancerOncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in the development of innovative oncology therapies, has recently completed enrollment and begun dosing for the fifth dose cohort in its Phase 1/2 study of ONCT-534. This study aims to evaluate the efficacy and safety of ONCT-534 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have relapsed or are refractory to approved androgen receptor pathway inhibitors (ARPI).Metastatic castration-resistant prostate cancer is a challenging and life-threatening condition that occurs...
February 1, 2024
In a recent press release, Oncternal Therapeutics, a prominent clinical-stage biopharmaceutical company specializing in the development of innovative oncology therapies, announced the approval of an inducement award for Damien Bresson. Bresson is joining Oncternal as the Senior Director of Preclinical and Translation Science. This article will outline the significance of this induction and assess its potential impact on the company s research and development endeavors.The appointment of Damien Bresson as the Senior Director of Preclinical and Translation Science demonstrates Oncternal Therapeutics commitment to strengthening its research team and advancing its position in the highly competitive field of onc...
Publicly Traded Peers of Oncternal Therapeutics Inc
Allakos Inc Share Performance
-73.46%
This Year
Allakos Inc
Profile
Allakos Inc's business model revolves around developing and commercializing innovative therapeutic antibodies to treat allergic and inflammatory diseases.
Pyxis Oncology Inc is a biotechnology company focused on developing innovative cancer therapies. Their business model revolves around leveraging novel insights into the immune system to develop a pipeline of potential immunotherapies for cancer treatment. Pyxis Oncology aims to collaborate with strategic partners to advance their therapies through preclinical and clinical development, ultimately aiming to improve patient outcomes in the field of oncology.
Janux Therapeutics Inc is a biotechnology company that focuses on developing and commercializing innovative cancer treatments. Their business model revolves around leveraging their expertise in immunotherapies and bispecific antibody platforms to create novel therapies that target tumor cells and activate the patient's immune system. By partnering with pharmaceutical companies and conducting clinical trials, they aim to bring effective and personalized cancer treatments to market.
United Therapeutics Corporation's business model revolves around the development and commercialization of innovative therapeutics for treating rare diseases and chronic conditions. They focus on researching, manufacturing, marketing, and distributing their specialized pharmaceutical and medical products to healthcare providers and patients globally.
Ligand Pharmaceuticals Inc operates on a business model focused on discovering and acquiring new drugs and technologies to license them to pharmaceutical companies. They generate revenue through licensing fees, milestone payments, and royalties from the sales of their partnered products. Their approach allows them to leverage their expertise and resources while minimizing risk, ultimately leading to long-term value creation for their shareholders.
Sources:
Oncternal Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Oncternal Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
